ACTRN12619000265178招募中4 期
Cannabinoids for Symptom Control in Advanced Cancer, an Open Label Prospective Clinical Trial in New South Wales (NSW)
Health Administration Corporation acting through the NSW Ministry of Health0 个研究点目标入组 600 人开始时间: 2019年2月21日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Aged 18 years or older.
- •2. Has provided written Informed Consent for participation in this trial.
- •3. Confirmed advanced cancer (any) with or without stable disease.
- •4. Predicted life expectancy of 3 to 12 months at time of consent, as estimated by the study investigator and confirmed by an additional qualified clinician, independent of the trial.
- •5. Persistent symptoms of anorexia, nausea or refractory pain, which in the investigator’s opinion are not responsive to implementation of standard practice, and who are ineligible or not wishing to be involved in other clinical trials of cannabis medicines.
- •6. Willing and able, in investigator’s opinion, to comply with all trial requirements, including keeping a patient diary, completing clinical measurement scales and having pharmacokinetic samples collected as per Participant Information Sheet. Note: completion of these trial requirements is essential and intentional non-compliance may cease access to trial product and will be managed on a case-by-case basis. Non-compliance due to declining health is unintentional and it is hoped unintentional noncompliance due to declining health may be minimised through optional proxy completion of patient reported outcomes and patient diary.
- •7. Available to attend Trial Site for follow up and collection of investigational product.
- •8. Participants (and/or partners) capable of childbearing are using adequate contraception.
- •Participants are able to continue to receive standard concomitant care and interventions, such as chemotherapy and radiotherapy, and take medications for other conditions as usual in the advanced care population
排除标准
- •1. Lack of capacity to consent.
- •2. Unwilling to keep a Patient Diary, attend follow up appointments, complete clinical measurement scales or have pharmacokinetic samples.
- •3. History of schizophrenia, other psychotic illness, severe borderline personality disorder, or other significant psychiatric disorder other than depression or anxiety associated with underlying condition. Delirium is an excluded condition.
- •4. Previous severe adverse event to any cannabinoid product, such as cannabis related psychosis, panic attack, palpitations.
- •5. A diagnosed substance use disorder (ICD-10 criteria (abuse, dependence)) to alcohol, opioids, cannabis, benzodiazepines, or illicit stimulants. Nicotine and caffeine are excluded.
- •6. Known allergy to cannabis or other ingredient of cannabis medicine e.g. carrier oil.
- •Note: Prior access to authorised cannabis medicines or current use of illicit cannabis is not an exclusion, unless associated with a serious adverse event (SAE) or substance use disorder as per exclusion criteria above.
研究者
相似试验
已完成
2 期
A study that evaluates the effectiveness of oral medicinal cannabis for people with advanced cancer experiencing a range of symptoms.FatigueNauseaBreathlessnessAppetitePsychological effectsCancer - Any cancerCancerACTRN12618001220257Mater Misericordiae Limited144
已完成
2 期
A study that evaluates the effectiveness of oral combined THC/CBD for people with advanced cancer experiencing a range of symptoms.FatigueNauseaBreathlessnessAppetitePsychological effectsCancer - Any cancerCancerACTRN12619000037101Mater Misericordiae Limited144
尚未招募
2 期
Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept StudyACTRN12614000248662SW5
进行中（未招募）
1 期
Cannabidiol as an add-on therapy in treatment-refractory psychotic disordersMedDRA version: 16.1Level: HLGTClassification code 10039628Term: Schizophrenia and other psychotic disordersSystem Organ Class: 10037175 - Psychiatric disordersSchizophreniaEUCTR2013-000240-26-GBKing's College London
进行中（未招募）
2 期
Cannabidiol for the treatment of patients at a high-risk of psychosisISRCTN10334895King’s College London and South London and Maudsley NHS Foundation Trust300